Table 1. Access to Any COVID-19 Vaccine in Countries With Completed COVID-19 Vaccine Clinical Trials Categorized by National Income Group (as of September 7, 2021).
| No. (%) | Proportion of population fully vaccinated with doses delivered of tested vaccine, median (IQR), %a,b | Countries procuring doses of tested vaccine via COVAX, No. (median % delivered of procurement) [IQR] | |||
|---|---|---|---|---|---|
| Countries that hosted COVID-19 vaccine clinical trials | Countries that authorized tested vaccine | Countries with doses delivered of tested vaccine | |||
| Completed clinical trials | |||||
| All | 25 | 23 (92.0) | 23 (92.0) | 39.4 (14.3-74.7) | 8 (78.8) [36.9-99.8] |
| Low income | 0 | NA | NA | NA | NA |
| Lower middle income | 3 (12.0) | 3 (100.0) | 3 (100.0) | 31.0 (18.1-37.6) | 1 (20.0) |
| Upper middle income | 11 (44.0) | 10 (90.9) | 10 (90.9) | 14.9 (7.2-48.6) | 6 (98.7) [69.4-99.9] |
| High income | 11 (44.0) | 10 (90.9) | 10 (90.9) | 51.7 (39.4-76.7) | 1 (38.0) |
| Ongoing and completed clinical trials | |||||
| All | 37 | 35 (94.6) | 35 (94.6) | 39.5 (14.3-74.7) | 16 (59.9) [36.9-99.0] |
| Low income | 1 (2.7) | 1 (100.0) | 1 (100.0) | 6.4 | 1 (15.4) |
| Lower middle income | 6 (16.2) | 6 (100.0) | 6 (100.0) | 20.2 (9.3-29.0) | 5 (48.8) [20.0-98.7] |
| Upper middle income | 12 (32.4) | 10 (90.9) | 10 (83.3) | 14.6 (1.6-55.4) | 6 (78.8) [55.3-99.2] |
| High income | 18 (48.6) | 18 (100.0) | 18 (100.0) | 67.9 (44.3-78.9) | 4 (67.1) [54.4-80.8] |
Abbreviations: COVAX, COVID-19 Vaccines Global Access; NA, not applicable.
a
Data at the country level for populations ages 15 to 64 years as well as 65 years and older were extracted from the World Population Dashboard hosted by the United Nations Population Fund. Data for populations ages 18 years and older as well as other specific age groups were unable to be extracted.
b
Data do not account for the population fully vaccinated with any COVID-19 vaccine, only the tested vaccine(s).